TY - STD TI - International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. UR - http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx ID - ref1 ER - TY - STD TI - Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. Toronto, ON; 2015. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2015-EN.pdf?la=en.  UR - http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2015-EN.pdf?la=en. ID - ref2 ER - TY - JOUR AU - Berry, D. A. AU - Cronin, K. A. AU - Plevritis, S. K. AU - Fryback, D. G. AU - Clarke, L. AU - Zelen, M. PY - 2005 DA - 2005// TI - Effect of screening and adjuvant therapy on mortality from breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa050518 DO - 10.1056/NEJMoa050518 ID - Berry2005 ER - TY - JOUR PY - 2011 DA - 2011// TI - Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials JO - Lancet VL - 378 UR - https://doi.org/10.1016/S0140-6736(11)60993-8 DO - 10.1016/S0140-6736(11)60993-8 ID - ref4 ER - TY - STD TI - Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–69. ID - ref5 ER - TY - STD TI - Hadji P, Ziller V, Kyvernitakis J, Bauer M, Haas G, Schmidt N, et al. Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis. Breast Cancer Res Treat. 2013;138:1–7. ID - ref6 ER - TY - STD TI - Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–37. ID - ref7 ER - TY - JOUR PY - 2005 DA - 2005// TI - Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials JO - Lancet VL - 365 UR - https://doi.org/10.1016/S0140-6736(05)66544-0 DO - 10.1016/S0140-6736(05)66544-0 ID - ref8 ER - TY - JOUR AU - Murphy, C. C. AU - Bartholomew, L. K. AU - Carpentier, M. Y. AU - Bluethmann, S. M. AU - Vernon, S. W. PY - 2012 DA - 2012// TI - Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review JO - Breast Cancer Res Treat VL - 134 UR - https://doi.org/10.1007/s10549-012-2114-5 DO - 10.1007/s10549-012-2114-5 ID - Murphy2012 ER - TY - STD TI - Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA, AK F, et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2004;22:3309–15. ID - ref10 ER - TY - STD TI - van Herk-Sukel MPP, van de Poll-Franse L V, Voogd AC, Nieuwenhuijzen GAP, Coebergh JWW, Herings RMC. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 2010;122:843–851. ID - ref11 ER - TY - JOUR AU - Hershman, D. L. AU - Kushi, L. H. AU - Shao, T. AU - Buono, D. AU - Kershenbaum, A. AU - Tsai, W. Y. PY - 2010 DA - 2010// TI - Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.9655 DO - 10.1200/JCO.2009.25.9655 ID - Hershman2010 ER - TY - JOUR AU - Kahn, K. L. AU - Schneider, E. C. AU - Malin, J. L. AU - Adams, J. L. AU - Epstein, A. M. PY - 2007 DA - 2007// TI - Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use JO - Med Care VL - 45 UR - https://doi.org/10.1097/01.mlr.0000257193.10760.7f DO - 10.1097/01.mlr.0000257193.10760.7f ID - Kahn2007 ER - TY - JOUR AU - Owusu, C. AU - Buist, D. S. M. AU - Field, T. S. AU - Lash, T. L. AU - Thwin, S. S. AU - Geiger, A. M. PY - 2008 DA - 2008// TI - Predictors of tamoxifen discontinuation among older women with estrogen receptor–positive breast cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2006.10.1022 DO - 10.1200/JCO.2006.10.1022 ID - Owusu2008 ER - TY - STD TI - Lambert LK, Balneaves LG, Howard AF, Gotay CC. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Breast Cancer Res Treat. 2018;167:615–633. ID - ref15 ER - TY - JOUR AU - Gotay, C. AU - Dunn, J. PY - 2011 DA - 2011// TI - Adherence to long-term adjuvant hormonal therapy for breast cancer JO - Expert Rev Pharmacoecon Outcomes Res VL - 11 UR - https://doi.org/10.1586/erp.11.80 DO - 10.1586/erp.11.80 ID - Gotay2011 ER - TY - STD TI - Brett J, Boulton M, Fenlon D, Hulbert-Williams NJ, Walter FM, Donnelly P, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence. 2018;12:291–300. ID - ref17 ER - TY - STD TI - Moon Z, Moss-Morris R, Hunter MS, Hughes LD. Understanding tamoxifen adherence in women with breast cancer: a qualitative study. Br J Health Psychol. 2017;22:978–97. ID - ref18 ER - TY - STD TI - Verbrugghe M, Verhaeghe S, Decoene E, De Baere S, Vandendorpe B, Van Hecke A. Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. Eur J Cancer Care (Engl). 2017;26:e12339. ID - ref19 ER - TY - STD TI - Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat. 2014;145:525–34. ID - ref20 ER - TY - STD TI - Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99:215–20. ID - ref21 ER - TY - STD TI - Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016;21:539–46. ID - ref22 ER - TY - STD TI - Huiart L, Bouhnik A-D, Rey D, Tarpin C, Cluze C, Bendiane MK, et al. Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed? Eur J Cancer. 2012;48:1939–46. ID - ref23 ER - TY - JOUR AU - Liu, Y. AU - Malin, J. L. AU - Diamant, A. L. AU - Thind, A. AU - Maly, R. C. PY - 2013 DA - 2013// TI - Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communication JO - Breast Cancer Res Treat VL - 137 UR - https://doi.org/10.1007/s10549-012-2387-8 DO - 10.1007/s10549-012-2387-8 ID - Liu2013 ER - TY - STD TI - Bradley CJ, Dahman B, Jagsi R, Katz S, Hawley S. Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer. Breast Cancer Res Treat. 2015;154:417–22. ID - ref25 ER - TY - STD TI - Huiart L, Bouhnik A-DD, Rey D, Rousseau F, Retornaz F, Meresse M, et al. Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. PLoS One. 2013;8:e81677. ID - ref26 ER - TY - JOUR AU - Friese, C. R. AU - Pini, T. M. AU - Li, Y. AU - Abrahamse, P. H. AU - Graff, J. J. AU - Hamilton, A. S. PY - 2013 DA - 2013// TI - Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer JO - Breast Cancer Res Treat VL - 138 UR - https://doi.org/10.1007/s10549-013-2499-9 DO - 10.1007/s10549-013-2499-9 ID - Friese2013 ER - TY - BOOK AU - Thorne, S. PY - 2016 DA - 2016// TI - Interpretive description: qualitative research for applied practice PB - Routledge CY - New York, NY ID - Thorne2016 ER - TY - CHAP AU - Sherwin, S. ED - Sherwin, S. PY - 1998 DA - 1998// TI - A relational approach to autonomy in health care BT - The politics of women’s health: exploring agency and autonomy PB - Temple University Press CY - Philadelphia ID - Sherwin1998 ER - TY - CHAP AU - Chan, A. AU - Speers, C. AU - O’Reilly, S. AU - Pickering, R. AU - Chia, S. K. PY - 2009 DA - 2009// TI - Adherence of adjuvant hormonal therapies in post-menopausal hormone receptor positive (HR+) early-stage breast cancer: a population based study from British Columbia BT - Program and abstracts of the 32nd annual San Antonio breast Cancer symposium ID - Chan2009 ER - TY - JOUR AU - Andersen, M. R. AU - Urban, N. PY - 1999 DA - 1999// TI - Involvement in decision-making and breast cancer survivor quality of life JO - Ann Behav Med VL - 21 UR - https://doi.org/10.1007/BF02884834 DO - 10.1007/BF02884834 ID - Andersen1999 ER - TY - JOUR AU - Thorne, S. PY - 2000 DA - 2000// TI - Data analysis in qualitative research JO - Evid Based Nurs VL - 3 UR - https://doi.org/10.1136/ebn.3.3.68 DO - 10.1136/ebn.3.3.68 ID - Thorne2000 ER - TY - JOUR AU - Sandelowski, M. PY - 2000 DA - 2000// TI - Focus on research methods-Whatever happened to qualitative description? JO - Res Nurs Health VL - 23 UR - https://doi.org/3.0.CO;2-G DO - 3.0.CO;2-G ID - Sandelowski2000 ER - TY - JOUR AU - Koch, T. PY - 2006 DA - 2006// TI - Establishing rigour in qualitative research: the decision trail JO - J Adv Nurs VL - 53 UR - https://doi.org/10.1111/j.1365-2648.2006.03681.x DO - 10.1111/j.1365-2648.2006.03681.x ID - Koch2006 ER - TY - STD TI - Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol 2010;28:3784–96. ID - ref35 ER - TY - JOUR AU - Partridge, A. H. AU - Wang, P. S. AU - Winer, E. P. AU - Avorn, J. PY - 2003 DA - 2003// TI - Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.07.071 DO - 10.1200/JCO.2003.07.071 ID - Partridge2003 ER - TY - JOUR AU - Barron, T. I. AU - Connolly, R. AU - Bennett, K. AU - Feely, J. AU - Kennedy, M. J. PY - 2007 DA - 2007// TI - Early discontinuation of tamoxifen JO - Cancer VL - 109 UR - https://doi.org/10.1002/cncr.22485 DO - 10.1002/cncr.22485 ID - Barron2007 ER - TY - JOUR AU - Aiello Bowles, E. J. AU - Boudreau, D. M. AU - Chubak, J. AU - Yu, O. AU - Fujii, M. AU - Chestnut, J. PY - 2012 DA - 2012// TI - Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer JO - J Oncol Pract VL - 8 UR - https://doi.org/10.1200/JOP.2012.000543 DO - 10.1200/JOP.2012.000543 ID - Aiello Bowles2012 ER - TY - JOUR AU - Chim, K. AU - Xie, S. X. AU - Stricker, C. T. AU - Li, Q. S. AU - Gross, R. AU - Farrar, J. T. PY - 2013 DA - 2013// TI - Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors JO - BMC Cancer VL - 13 UR - https://doi.org/10.1186/1471-2407-13-401 DO - 10.1186/1471-2407-13-401 ID - Chim2013 ER - TY - STD TI - Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19:322–8. ID - ref40 ER - TY - STD TI - Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer. 2014;120:2403–11. ID - ref41 ER - TY - STD TI - Bender CM, Gentry AL, Brufsky AM, Casillo FE, Cohen SM, Dailey MM, et al. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum. 2014;41:274–85. ID - ref42 ER - TY - STD TI - Harrow A, Dryden R, McCowan C, Radley A, Parsons M, Thompson AM, et al. A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer. BMJ Open. 2014;4:e005285. ID - ref43 ER - TY - JOUR AU - Pellegrini, I. AU - Sarradon-Eck, A. AU - Soussan, P. B. AU - Lacour, A. C. AU - Largillier, R. AU - Tallet, A. PY - 2010 DA - 2010// TI - Women’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view JO - Psychooncology VL - 19 UR - https://doi.org/10.1002/pon.1593 DO - 10.1002/pon.1593 ID - Pellegrini2010 ER - TY - STD TI - Wickersham K, Happ MB, Bender CM. “Keeping the boogie man away”: medication self-management among women receiving anastrozole therapy. Nurs Res Pract; 2012. https://doi.org/10.1155/2012/462121. ID - ref45 ER - TY - STD TI - Hershman DL, Kushi LH, Hillyer GC, Coromilas E, Buono D, Lamerato L, et al. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat. 2016;157:133–43. ID - ref46 ER - TY - JOUR AU - Cella, D. AU - Fallowfield, L. J. PY - 2008 DA - 2008// TI - Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy JO - Breast Cancer Res Treat VL - 107 UR - https://doi.org/10.1007/s10549-007-9548-1 DO - 10.1007/s10549-007-9548-1 ID - Cella2008 ER - TY - STD TI - Syrjala KL, Jensen MP, Mendoza ME, Yi JC, Fisher HM, Keefe FJ. Psychological and behavioral approaches to cancer pain management. J Clin Oncol. 2014;32:1703–11. ID - ref48 ER - TY - STD TI - Beryl LL, Rendle KAS, Halley MC, Gillespie KA, May SG, Glover J, et al. Mapping the decision-making process for adjuvant endocrine therapy for breast cancer. Med Decis Mak. 2017;37:79–90. ID - ref49 ER - TY - STD TI - Brauer ER, Ganz PA, Pieters HC. “Winging it”: how older breast cancer survivors persist with aromatase inhibitor treatment. J Oncol Pract. 2016;12:e991–1000. ID - ref50 ER - TY - JOUR AU - Farias, A. J. AU - Ornelas, I. J. AU - Hohl, S. D. AU - Zeliadt, S. B. AU - Hansen, R. N. AU - Li, C. I. PY - 2017 DA - 2017// TI - Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis JO - Support Care Cancer VL - 25 UR - https://doi.org/10.1007/s00520-016-3389-6 DO - 10.1007/s00520-016-3389-6 ID - Farias2017 ER - TY - STD TI - Ayres LR, Baldoni AO, Borges APS, Pereira LRL. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm. 2014;36:45–54. ID - ref52 ER - TY - STD TI - Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L. Women’s experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer. 2015;23:3115–30. ID - ref53 ER - TY - STD TI - Wells KJ, Pan TM, Vázquez-Otero C, Ung D, Ustjanauskas AE, Muñoz D, et al. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer. 2016;24:4123–30. ID - ref54 ER - TY - STD TI - Arriola KRJ, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K, et al. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns. 2014;95:98–103. ID - ref55 ER - TY - STD TI - Grant M, Economou D, Ferrell BR. Oncology nurse participation in survivorship care. Clin J Oncol Nurs. 2010;14:709–15. ID - ref56 ER - TY - JOUR AU - Albert, U. -. S. AU - Zemlin, C. AU - Hadji, P. AU - Ziller, V. AU - Kuhler, B. AU - Frank-Hahn, B. PY - 2011 DA - 2011// TI - The impact of breast care nurses on patients’ satisfaction, understanding of the disease, and adherence to adjuvant endocrine therapy JO - Breast Care VL - 6 UR - https://doi.org/10.1159/000329006 DO - 10.1159/000329006 ID - Albert2011 ER - TY - STD TI - Luctkar-Flude M, Aiken A, McColl MA, Tranmer J. A comprehensive framework and key guideline recommendations for the provision of evidence-based breast cancer survivorship care within the primary care setting. Fam Pract. 2015;32:129–40. ID - ref58 ER -